Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Coherus Biosciences Inc - SIC # 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS
Ticker
Exchange
SIC #
Website
Latest Ticker
CHRS
Nasdaq
2833
https://www.coherus.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Coherus Biosciences Inc
Coherus BioSciences Announces New Employment Inducement Grants
- Feb 3rd, 2023 10:30 pm
'Go big or go home': How a Peninsula biotech looks to win in Humira biosimilar 'feeding frenzy'
- Jan 30th, 2023 10:57 pm
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
- Jan 9th, 2023 1:20 pm
Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Jan 4th, 2023 12:01 pm
Should You Invest in Coherus BioSciences (CHRS)?
- Jan 3rd, 2023 12:12 pm
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
- Dec 25th, 2022 1:16 pm
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
- Dec 24th, 2022 5:01 am
With 74% institutional ownership, Coherus BioSciences, Inc. (NASDAQ:CHRS) is a favorite amongst the big guns
- Dec 21st, 2022 11:52 am
Coherus BioSciences Third Quarter 2022 Earnings: Misses Expectations
- Nov 10th, 2022 11:18 am
Coherus BioSciences (CHRS) Reports Q3 Loss, Lags Revenue Estimates
- Nov 8th, 2022 10:25 pm
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
- Nov 8th, 2022 9:01 pm
Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022
- Nov 1st, 2022 11:30 am
Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 55% over the last three years
- Oct 18th, 2022 2:48 pm
Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology
- Oct 12th, 2022 11:30 am
Will Coherus BioSciences (CHRS) Stock Bounce Back?
- Oct 10th, 2022 3:49 pm
Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022
- Sep 19th, 2022 11:30 am
Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference
- Sep 12th, 2022 12:30 pm
Here's Why Coherus BioSciences (CHRS) Looks Ripe for Bottom Fishing
- Sep 2nd, 2022 1:55 pm
Wall Street Analysts Think Coherus BioSciences (CHRS) Could Surge 47%: Read This Before Placing a Bet
- Aug 19th, 2022 1:55 pm
Coherus BioSciences (CHRS) Q2 2022 Earnings Call Transcript
- Aug 6th, 2022 9:00 am
Scroll